United States - English - NLM (National Library of Medicine)

carilion materials management - ramipril (unii: l35jn3i7sj) (ramiprilat - unii:6n5u4qfc3g) - ramipril 1.25 mg - ramipril is indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - ramipril (unii: l35jn3i7sj) (ramiprilat - unii:6n5u4qfc3g) - ramipril 5 mg - ramipril capsules are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a variety of pharmacologic classes and with different

United States - English - NLM (National Library of Medicine)

atlantic biologicals corps - ramipril (unii: l35jn3i7sj) (ramipril - unii:l35jn3i7sj) - ramipril 5 mg - ramipril capsules usp are indicated for the treatment of hypertension. it may be used alone or in combination with thiazide diuretics. ramipril capsules usp are contraindicated in patients who are hypersensitive to this product or any other ace inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ace inhibitor). ingestion of a single 10 mg oral dose of ramipril resulted in undetectable amounts of ramipril and its metabolites in breast milk. however, because multiple doses may produce low milk concentrations that are not predictable from a single dose, do not use ramipril in nursing mothers. safety and effectiveness in pediatric patients have not been established. irreversible kidney damage has been observed in very young rats given a single dose of ramipril. of the total number of patients who received ramipril in us clinical studies of ramipril 11% were ≥65 years of age while 0.2% were ≥75 years of age. no overall differences in effectiveness or safety were observed between

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - ramipril, quantity: 10 mg - tablet, uncoated - excipient ingredients: sodium stearylfumarate; pregelatinised maize starch; sodium bicarbonate; microcrystalline cellulose; hypromellose - treatment of hypertension. data are currently not available to support the use of ramipril in renovascular hypertension. post mi heart failure. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke, or peripheral vascular disease. for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160mmhg or diastolic blood pressure >90mmhg (or an antihypertensive treatment); total cholesterol >5.2mmol/l; hdl cholesterol <0.9mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - ramipril, quantity: 5 mg - tablet, uncoated - excipient ingredients: sodium bicarbonate; microcrystalline cellulose; sodium stearylfumarate; hypromellose; pregelatinised maize starch - treatment of hypertension. data are currently not available to support the use of ramipril in renovascular hypertension. post mi heart failure. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke, or peripheral vascular disease. for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160mmhg or diastolic blood pressure >90mmhg (or on antihypertensive treatment); total cholesterol >5.2mmol/l; hdl cholesterol <0.9mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - ramipril, quantity: 2.5 mg - tablet, uncoated - excipient ingredients: pregelatinised maize starch; sodium stearylfumarate; microcrystalline cellulose; hypromellose; sodium bicarbonate - treatment of hypertension. data are currently not available to support the use of ramipril in renovascular hypertension. post mi heart failure. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke, or peripheral vascular disease. for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160mmhg or diastolic blood pressure >90mmhg (or on antihypertensive treatment); total cholesterol >5.2mmol/l; hdl cholesterol <0.9mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - ramipril, quantity: 1.25 mg - tablet, uncoated - excipient ingredients: sodium bicarbonate; pregelatinised maize starch; hypromellose; microcrystalline cellulose; sodium stearylfumarate - treatment of hypertension. data are currently not available to support the use of ramipril in renovascular hypertension. post mi heart failure. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke, or peripheral vascular disease. for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160mmhg or diastolic blood pressure >90mmhg (or on antihypertensive treatment); total cholesterol >5.2mmol/l; hdl cholesterol <0.9mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Malta - English - Medicines Authority

tad pharma gmbh heinz-lohmann-strasse 5, 27472 cuxhaven, germany - ramipril, hydrochlorothiazide - tablet - ramipril 2.5 mg hydrochlorothiazide 12.5 mg - agents acting on the renin-angiotensin system

Malta - English - Medicines Authority

tad pharma gmbh heinz-lohmann-strasse 5, 27472 cuxhaven, germany - ramipril, hydrochlorothiazide - tablet - ramipril 5 mg hydrochlorothiazide 25 mg - agents acting on the renin-angiotensin system

Malta - English - Medicines Authority

tad pharma gmbh heinz-lohmann-strasse 5, 27472 cuxhaven, germany - ramipril - tablet - ramipril 1.25 mg - agents acting on the renin-angiotensin system